Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences in August

Rhea-AI Summary

Corbus Pharmaceuticals Holdings (NASDAQ: CRBP) has announced its participation in two upcoming investor conferences in August 2024. CEO Yuval Cohen, Ph.D., will provide corporate updates and engage in investor meetings at these events:

1. BTIG Virtual Biotechnology Conference (August 5-6, 2024): Invitation-only, one-on-one investor meetings.

2. Wedbush PacGrow Healthcare Conference (August 13-14, 2024): Invitation-only, one-on-one and small group investor meetings.

Interested investors should contact their respective BTIG or Wedbush representatives to arrange meetings with Corbus management during these conferences.

NORWOOD, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in two investor conferences during the month of August. Dr. Cohen will provide a corporate update and participate in one-on-one investor meetings at the following events.

BTIG Virtual Biotechnology Conference

Date: August 5-6, 2024
Format: Invitation only, one-on-one investor meetings
Note: Investors interested in attending and meeting with management should contact their BTIG representatives.

Wedbush PacGrow Healthcare Conference

Date: August 13-14, 2024
Format: Invitation only, one on one and small group investor meetings
Note: Investors interested in attending and meeting with management should contact their Wedbush representatives.

About Corbus
Corbus Pharmaceuticals Holdings, Inc. is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus’ pipeline includes CRB-701, a next generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody which blocks the activation of TGFβ expressed on cancer cells, and CRB-913, a highly peripherally restricted CB1 receptor inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on Twitter, LinkedIn and Facebook.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's trial results, product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential,” "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

All product names, logos, brands and company names are trademarks or registered trademarks of their respective owners. Their use does not imply affiliation or endorsement by these companies.

INVESTOR CONTACT:

Sean Moran
Chief Financial Officer
Corbus Pharmaceuticals
Sean.moran@corbuspharma.com

Bruce Mackle
Managing Director
LifeSci Advisors, LLC
bmackle@lifesciadvisors.com

FAQ

When is Corbus Pharmaceuticals (CRBP) participating in investor conferences in August 2024?

Corbus Pharmaceuticals (CRBP) is participating in two investor conferences in August 2024: the BTIG Virtual Biotechnology Conference on August 5-6, and the Wedbush PacGrow Healthcare Conference on August 13-14.

Who will represent Corbus Pharmaceuticals (CRBP) at the August 2024 investor conferences?

Yuval Cohen, Ph.D., Chief Executive Officer of Corbus Pharmaceuticals (CRBP), will represent the company at the August 2024 investor conferences.

What type of meetings will Corbus Pharmaceuticals (CRBP) hold at the BTIG Virtual Biotechnology Conference?

Corbus Pharmaceuticals (CRBP) will hold invitation-only, one-on-one investor meetings at the BTIG Virtual Biotechnology Conference on August 5-6, 2024.

How can investors meet with Corbus Pharmaceuticals (CRBP) management at the Wedbush PacGrow Healthcare Conference?

Investors interested in meeting with Corbus Pharmaceuticals (CRBP) management at the Wedbush PacGrow Healthcare Conference on August 13-14, 2024, should contact their Wedbush representatives to arrange meetings.